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This study in people following curative intent treatment for non-small cell lung cancer 
(NSCLC) aimed to; (i) compare both the magnitude of impairment in exercise capacity 
and exercise responses measured during the six-minute walk test (6MWT) and the 
cardiopulmonary exercise test (CPET), and (ii) investigate the effect of test repetition on 
six-minute walk distance (6MWD). Twenty participants (67±10yr; 14 females), 6-10 
weeks following lobectomy, underwent a CPET and two 6MWTs. Peak exercise 
responses, dyspnoea and leg fatigue as well as heart rate (HR) and oxygen saturation 
(SpO2) during the 6MWT were compared to those during the CPET. Compared with 
exercise capacity expressed as peak rate of oxygen consumption (VO2peak) (%pred) 
measured during the CPET, exercise capacity was less impaired when expressed as 
6MWD (%pred) (81±10 versus  63±15%pred; p<0.001). Compared with the CPET, the 
6MWT elicited lower peak HR (119±15 versus 128±18bpm; p=0.02), lower SpO2 (93±2 
versus 95±3%; p<0.05), less dyspnoea (3.1±1.6 versus 6.9±2.6; p<0.01) and less leg 
fatigue (2.0±1.9 versus 6.8±2.4; p<0.01). The 6MWD increased 19±19m (4±4%) with 
test repetition (p<0.001). In people following curative intent treatment for NSCLC, the 
6MWT appears to elicit sub-maximal exercise responses when compared with the 
CPET. There is a significant effect of test repetition on 6MWD.  




Lung cancer is the most common cause of death from malignancy in males and 
females.1 For people diagnosed with early stage non-small cell lung cancer (NSCLC) 
(i.e. stages I-IIIA), surgical resection of the tumour (with or without adjuvant 
chemotherapy) offers a chance of cure.2 Although the overall 5-year survival rate for 
people with lung cancer is approximately 15%,1, 3 for those with early stage NSCLC 
who complete curative intent treatment, the 5-year survival rate can be as high as 80%.2 
Therefore, in people following curative intent treatment for early stage NSCLC interest 
is increasing in the impact such treatment has on functional status, as well as the role 
rehabilitative strategies, such as exercise training, may have in optimising recovery. 
Specifically, earlier work has demonstrated that people who have completed curative 
intent treatment for NSCLC have substantial impairments in exercise capacity.4-10 
Compared to pre-operative values, the peak rate of oxygen uptake (VO2peak) following 
lung resection is reduced by 10 to 28%.8-10 Further, there have been some randomised 
controlled trials, and a recent Cochrane review, that have investigated whether this 
impairment in exercise capacity can be ameliorated with exercise training.11-13  
 
Although there is interest in exercise capacity and the role of exercise training in this 
population, data exploring the responses to exercise in people following curative intent 
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treatment for NSCLC are scarce. The cardiopulmonary exercise test (CPET) is a 
laboratory-based assessment which provides a global assessment of an individuals’ 
response to exercise.14 Even though several protocols exist, those which impose a 
progressive increase in work rate are most common. The CPET is accepted as the gold 
standard method to quantify exercise capacity and the results can be used to prescribe 
the initial intensity for exercise training.14 It is however, expensive to perform and 
requires access to specialised equipment and personnel. Therefore, the six-minute walk 
test (6MWT), in which an individual to asked to walk as far as possible in six minutes, 
is commonly used in pulmonary rehabilitation programmes to quantify exercise 
capacity and prescribe the initial intensity for walking-based exercise training.15-17  
 
Studies in people with moderate-to-severe chronic obstructive pulmonary disease 
(COPD) that have compared exercise responses during the 6MWT to those during the 
CPET18-23 have shown no difference in VO2peak
18, 19, 21 and either minimal22 or no 
difference18-21, 23 in peak heart rate (HR) between the two tests. In people with COPD, 
although the 6MWT has been shown to elicit similar peak responses as the CPET, 
walking-based exercise training is often prescribed and tolerated at a high percentage 
(e.g. 80%) of the average speed achieved during the 6MWT.24, 25 In people following 
curative intent treatment for NSCLC, no studies have compared the exercise responses 
measured during the CPET and the 6MWT. Hence, it is unknown whether the 6MWT 
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elicits peak or sub-maximal exercise responses, relative to the CPET. Such information 
will assist clinicians to decide whether it is appropriate to prescribe walking-based 
exercise training at 80% of the average speed achieved during the 6MWT, or whether a 
higher initial intensity may be tolerated in this population.  
 
The European Respiratory Society/American Thoracic Society (ERS/ATS) technical 
standard on field walking tests26 recommends that the 6MWT should be performed 
twice to account for any effect test repetition may have on six-minute walk distance 
(6MWD). However, this recommendation is based largely on studies that recruited 
people with COPD.26, 27 No studies have explored the effect of test repetition on 6MWD 
in people following curative intent treatment for NSCLC.  
 
Therefore, in people following curative intent treatment for NSCLC, the aims of this 
study were to; (i) compare the magnitude of impairment in exercise capacity and 
exercise responses measured during the 6MWT and CPET, and (ii) investigate the effect 
of test repetition on 6MWD. As we collected several cardiorespiratory variables during 






Study design and participants 
This was a cross-sectional and observational study. Data collection was performed 
between February 2012 and April 2014. People were included if they were 6 to 10 
weeks following lobectomy for NSCLC (stage I-IIIA) or, for those who required 
adjuvant chemotherapy following surgery, 4 to 8 weeks following their last treatment. 
Exclusion criteria comprised; presence of co-morbid conditions that may compromise 
safety during the assessments, severe neuromusculoskeletal limitations or the inability 
to understand spoken or written English. All participants gave written informed consent. 
The study was approved by the Ethics Committees of two tertiary hospitals (approval 
numbers 2011/105 and RA-11/033) and Curtin University (HR-178/2011). 
 
Protocol 
Measures were collected over 2 assessment days, separated by at least 7 days. On the 
first day age, height and weight were recorded, functional limitation resulting from 
dyspnoea was assessed by the modified Medical Research Council dyspnoea scale 
(MMRC),28, 29 and participants underwent two 6MWTs. On the second day, measures 
were made of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) 
and single breath diffusing capacity for carbon monoxide (The Elite-Series-DX-
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plethysmograph, Medical Graphics Corporation, USA)30-34 and participants completed a 
CPET.   
 
Exercise capacity measures 
Cardiopulmonary exercise test 
A symptom-limited ramp cycle ergometry exercise test was performed on an 
electronically braked bicycle ergometer (ER-900 Jaeger, Viasys-Healthcare-GmbH, 
Germany) in accordance with published guidelines.14 The magnitude of work rate 
increments was individualised using a published equation,35 with the goal of achieving a 
test duration of 10 minutes.14, 35, 36 Increments varied from 1 watt (W) every 12 seconds 
to 1W every 5 seconds. Participants rested on the bike for 3 minutes, then completed 
unloaded cycling (between 50-60rpm) for 3 minutes, after which time the resistance on 
the bike progressively increased until symptom limitation. Breath-by-breath 
measurements were collected (Medgraphics-CardiO2; Medical Graphics Corporation, 
USA). Blood pressure was measured every 2 minutes by automated 
sphygmomanometry, HR was measured via twelve-lead electrocardiography and 
peripheral capillary oxygen saturation (SpO2) was continuously monitored via pulse 
oximetry (Rad4; Masimo Corporation, USA). The modified BORG scale (0-10)37 was 
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used to quantify the level of dyspnoea (BORGd) and leg fatigue (BORGf) prior to 
starting the test, each minute during the test, and on test completion.  
 
Measures of oxygen uptake and minute ventilation collected over the final 20 seconds 
previous to their highest value were averaged to calculate VO2peak and maximum minute 
ventilation (VEmax).14, 38, 39 Measures of maximum work rate (Wmax) and VO2peak were 
expressed in absolute values and as a percentage of the predicted value.40 A single 
CPET was completed as studies in healthy people and in people with COPD have 
shown no improvement when a second test was performed.14  
 
Six-minute walk test  
The 6MWT was undertaken according to the ERS/ATS recommendations,26 with 
encouragement to walk as far and as fast as possible. The test was performed over a 45-
m straight course within an enclosed corridor, which is consistent with the course used 
to develop the reference equations for the Australian population.41 Standardised 
encouragement was given at the end of every minute. Also, at the end of every minute, 
measures were collected of HR (Polar-a1; Polar Electro Oy, Finland) and SpO2 (Rad-
57; Masimo Corporation, USA). The modified BORG scale37 was used to quantify level 
of dyspnoea and leg fatigue prior to starting the test and on test completion.  
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Two tests, separated by a 30-minute rest period, were conducted and the best 6MWD 
was recorded as the test result. Further, the six-minute walk work (6MWW) was 
calculated as the product of 6MWD (expressed in km) and weight (expressed in kg). 
This variable represents the work of walking.42 For each participant, the 6MWD was 
expressed in absolute values and as a percentage of their predicted value.41 
 
Statistical analysis 
Statistical analyses were performed using SPSS® (Statistical Package for Social 
Sciences, version 22.0) and SigmaPlot (version 12.0). The distribution of data was 
examined using the Shapiro-Wilk test. Exercise capacity, peak HR, nadir SpO2, end-test 
BORGd and BORGf elicited during the two tests were compared using paired t-tests. 
Differences between the exercise tests are expressed as mean difference (MD) [95% 
confidence interval (CI)]. Clinically important oxygen desaturation during the 6MWT 
and CPET was defined as a >4% fall in SpO2 from resting measures, to a value <90%.
43 
A subgroup analysis comparing exercise responses during the two tests in people 
diagnosed with COPD44 versus people not diagnosed with COPD was undertaken using 
an independent t-test. In order to compare the patterns of changes in measures of HR 
and SpO2 during each test, data were grouped into deciles (i.e. epochs equivalent to 10% 
of the total test duration) using a two-dimensional data transformation. Comparison of 
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both HR and SpO2 at each decile throughout the 6MWT and the CPET was performed 
using a one-way repeated measures analysis of variance with Tukey’s post-hoc. 
Correlations between variables from the 6MWT (i.e. 6MWD and 6MWW) and 
variables from the CPET (i.e. VO2peak and Wmax) were calculated utilising Pearson’s 
correlation coefficient (see online supplementary material). The effect of test repetition 
on 6MWD was examined using a paired t-test. For all analyses, a p value ≤0.05 was 
considered significant. Data are expressed as meanstandard deviation (SD).  
 
This study represents a secondary analysis of data collected as part of a larger study that 
compared several outcomes in people following curative intent treatment for NSCLC 
with those in age and gender-matched healthy controls.45 For the larger study,45 the 
sample size calculation indicated that 18 participants with NSCLC and 18 healthy 
controls were needed to detect a between-group difference in VO2peak of 0.55 L·min
-1 
with a standard deviation of 0.57 L·min-1 (α = 0.05, 1 - β = 0.8). Data collected in the 
participants with NSCLC who completed this larger study were used in the analyses 




Ninety-six people following lobectomy were screened to participate in this study, of 
whom 71% (n=68) were eligible and approached. Of these, 22 (32%) consented to 
participate. The reasons for declining participation were; (i) difficulty with travelling to 
the hospital (n=16), (ii) no free time to attend assessments (n=11), (iii) lack of interest 
(n=11), (iv) personal issues (n=6), and (v) travelling overseas for the next couple of 
weeks (n=2). Two of the 22 were withdrawn due to health issues not related to lung 
cancer. Complete CPET and 6MWT data were available in 20 participants. The first 
assessment day ocurred 56±18 days following lobectomy. One participant received 
chemotherapy and their first assessment day ocurred 28 days following their last cycle 
of chemotherapy. Characteristics of the participants are presented in Table 1. Their 
median (interquartile range) MMRC grade was 1 (1 to 1.75). Ten participants (50%) 
had a diagnosis of COPD. Their characteristics are presented in the online 
supplementary material.  
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Cardiopulmonary exercise test 
Results of the CPET are shown in Table 2 and Table 3. One participant (5%) 
desaturated >4% to a SpO2 of 87% during the test. There was no difference between 
end-test BORGd (6.9±2.6) and end-test BORGf (6.8±2.4) (p=0.87). A total of four 
(20%) participants demonstrated evidence of a ventilatory limitation to exercise, defined 
as a ratio of VEmax to maximum voluntary ventilation (VEmax/MVV) of > 85%.14 
These participants had spirometric evidence of COPD.  
 
Six-minute walk test 
Results of the best 6MWT are shown in Table 2 and Table 3. Two participants (10%) 
desaturated >4% to a SpO2 <90% during the test. There was no difference between end-
test BORGd (3.1±1.6) and end-test BORGf (2.0±1.9) (p=0.06).  
 
Comparison of exercise responses during the two exercise tests  
The impairment in exercise capacity expressed in terms of VO2peak was greater than the 
impairment expressed in terms of 6MWD (63±15 versus 81±10%predicted; p<0.001). 
Table 3 presents a comparison of HR, SpO2 and symptoms between the two tests. 
Compared with responses measured during the CPET, the 6MWT elicited a lower peak 
HR (MD [95% CI]; -9[-16 to -1]bpm; p=0.02) and greater oxygen desaturation (MD 
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[95% CI] nadir SpO2; -2[-4 to -1]%; p=0.01). Both the BORGd and BORGf were also 
lower on completion of the 6MWT (MD [95% CI]; -4[-5 to -3] and -5[-6 to -3], 
respectively; p<0.001 for both). 
The pattern of change in HR and SpO2 during the two tests is presented in Figure 1. 
During the CPET, HR increased linearly with time whereas, during the 6MWT, HR 
increased from the beginning of the test until the end of the third minute (∆HR; 
32±12bpm; p<0.001) after which, there was a plateau until test completion (∆HR 
between the end of the third minute and test completion; 4±4bpm; p=0.34). During the 
CPET, there was a linear decrease in SpO2 whereas, during the 6MWT, there was a 
reduction in SpO2 from the beginning of the test until the end of the second minute 
(∆SpO2; -3±2%; p=0.01) after which, there was a plateau until test completion (∆SpO2 
between the end of the second minute and test completion; -1±1%; p=0.67). 
 
Effect of test repetition on 6MWD 
The 6MWD increased with test repetition from 484±72 to 503±71m; p<0.001. The 
mean difference was 19±19m (range: -8 to 57m) or 4±4% (range: -2 to 20%).  Eighteen 
of the 20 participants (90%) walked further on the second 6MWT. None of the 




Subgroup analyses comparing responses of people with COPD to people without 
COPD 
No difference between those with and without COPD were found in any of the exercise 




The important findings of this study are that in people following curative intent 
treatment for NSCLC; (i) the impairment in exercise capacity measured during the 
CPET, expressed as VO2peak (% predicted) was considerably greater than the 
impairment expressed as 6MWD (% predicted), (ii) the causes of exercise limitation 
were variable with a small proportion of participants demonstraing evidence of 
ventilatory limitation, (iii) compared with the CPET, the 6MWT elicited a lower peak 
HR, less symptoms of dyspnoea and leg fatigue, but greater oxygen desaturation, and 
(iv) the 6MWD increased with test repetition.  Differences in the pattern of response in 
HR and SpO2 were observed during the CPET and 6MWT.  
During the CPET, people following curative intent treatment for NSCLC achieved a 
VO2peak of 15±3 ml·kg
-1·min-1 or 63±15% predicted. The impairment in 6MWD was 
less, being 503±71 m or 81±10% predicted. Therefore, it seems that people following 
curative intent treatment for NSCLC have considerable impairment in peak exercise 
capacity, but relatively modest impairment in the capacity to walk as far as possible in 6 
minutes. Regarding the mechanisms of exercise limitation, four (20%) participants, all 
of whom had evidence of COPD, demonstrated evidence of a ventilatory limitation. 
Although the other six participants with spirometric evidence of COPD did not 
demonstrate a ventilatory limitation, we cannot be certain that they did not develop lung 
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hyperinflation during exercise as we did not perform flow-volume loops or monitor 
changes in inspiratory capacity. Earlier work has shown that people with mild COPD 
progressively develop lung hyperinflation during exercise and this contributes to their 
sensation of dyspnoea.46 In those without COPD, the most likely mechanism of 
limitation was peripheral muscle deconditioning.  
Our data show that compared with the CPET, the 6MWT elicited a lower peak HR and 
less symptoms. This is different to earlier work in people with COPD, which shows that 
the CPET and 6MWT elicit a similar peak HR as their ventilatory limitation to exercise 
precludes them from attaining a higher peak HR during the CPET.18, 19 The implications 
these findings are three-fold. First, for clinicians who are unable to access CPET, people 
following curative intent treatment for NSCLC who present with modest impairments in 
6MWD may have considerable impairment in peak exercise capacity, and therefore may 
still benefit from participating in exercise training. Second, given that the mean 6MWD 
was greater than 500m, or 80%predicted, it is possible that this test is not as responsive 
as it is in people with moderate-to-severe COPD to change following exercise 
training.47 Although earlier work in people with bronchiectasis, who were characterised 
by a high baseline 6MWD, demonstrated an increase in 6MWD of 41m (95%CI 19 to 
63m) following 8 weeks of exercise training,48 alternative field-based tests, such as the 
modified incremental shuttle walk test49 may be more responsive to change following 
interventions. Third, the way in which the 6MWD has been used to prescribe the 
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intensity of walking-based training in people with COPD may require some 
reconsideration in people following curative intent treatment for NSCLC. That is, in 
people with COPD, although the 6MWT has been shown to elicit similar peak 
responses as the CPET, walking-based exercise training is often prescribed at a high 
percentage (e.g. 80%) of the average speed achieved during the 6MWT.24 In contrast, 
our data shows that in people following curative intent treatment for NSCLC, the 
6MWT elicited sub-maximal responses. As the 6MWT is a sub-maximal test in this 
population, it is likely that they will tolerate an initial prescription of walking-based 
training at any intensity greater than that used for COPD.25   
The magnitude of impairment in VO2peak and 6MWD between those with and without 
COPD was very similar. Although the lack of statistical difference is likely to reflect the 
small sample size available for this comparison, the data suggest that any difference is 
very small and unlikely to be clinically meaningful. The similarity in measures between 
those with versus without COPD may also relate to the fact that our sample included 
individuals with mild-to-moderate, rather than severe airflow obstruction. 
Although the extent of oxygen desaturation observed during both tests was modest, the 
SpO2 of people following curative intent treatment for NSCLC decreased to a greater 
extent during the 6MWT. Greater desaturation during walking compared with cycle 
based exercise corroborates the findings of previous studies in people with moderate-to-
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severe COPD.18-21, 50 Had the CPET been performed on a treadmill, it is unlikely that 
the decrease in SpO2 would have been different between the two tests.
51 The finding of 
greater oxygen desaturation during the 6MWT in this study may relate to both the larger 
muscle mass involved in walking compared to cycling and the specific load imposed on 
the quadriceps during cycle based exercise, which results in a significant concentration 
of blood lactate on test completion, heightening the ventilatory response.52 The specific 
load on the quadriceps is likely to explain the greater severity of symptoms seen during 
the CPET and the higher level of ventilation previously reported during cycle based 
exercise serves to minimise the extent of desaturation.51, 53  
This study revealed clear differences in patterns of HR and SpO2 responses during the 
6MWT compared to the CPET. Whilst HR and SpO2 during the CPET changed 
gradually and linearly with time, during the 6MWT these two variables changed 
exponentially over the first 2 to 3 minutes of the test, followed by a relative plateau until 
test completion. These patterns of response are consistent with data reported in people 
with moderate-to-severe COPD,18, 19 and reflect the way in which these tests are 
conducted. That is, compared to the CPET in which work rate increases in a linear 
fashion, work rate during the 6MWT is almost constant after the initial acceleration.19, 54 
Consistent with earlier work in COPD, both Wmax and VO2peak were associated with 
6MWD. The strength of this association increased when work done during the 6MWT 
was considered by using the variable 6MWW.42, 55  
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Our data demonstrated that there was a significant effect of test repetition. The 6MWD 
improved by an average of 19m (or 4%) on the second test. This is consistent with 
findings from studies in people with COPD (mean increase ranges from 13 to 37m or 4 
to 11%)22, 56, 57 and idiopathic pulmonary fibrosis (mean increase reported to be 11m or 
4%).22 This finding supports that a minimum of two 6MWT should be used when 
assessing people following curative intent treatment for NSCLC.  
Limitations 
Although our sample size was somewhat modest, it was similar to that of previous 
studies that have compared responses during the CPET to those during field-based walk 
tests in people with COPD (sample size ranged from 20 to 24 participants)18-20 and 
greater than a previous study in people with heart failure (n=15).58 We acknowledge 
that the sample may not be large enough to detect differences between the subgroup of 
people with COPD and the subgroup of people who did not have COPD. We also 
acknowledge that the use of reference equations to quantify impairment in exercise 
capacity has its limitations. That is, differences in sample characteristics, equipment and 
assessment protocols between the study that developed the regression equations and the 
current study may have introduced error to our estimate of impairment, expressed as a 
percentage of the predicted value in a healthy population. As measures of exercise 
capacity were not collected prior to and following a specific intervention, we were not 
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able to investigate the responsiveness of the two tests. The need for a third 6MWT was 
not assessed, however data from previous study in people with COPD demonstrated no 
significant increase in distance on a third test.20 Another limitation is that ventilatory 
and metabolic responses during the 6MWT were not measured using a portable gas 
analysis system. Additionally, people who underwent wedge resection or 
pneumonectomy for NSCLC were not included in the study, thus the results cannot be 
extended to all people undergoing lung resection for NSCLC. 
In conclusion, this study demonstrated that people following curative intent treatment 
for NSCLC presented with greater impairment in exercise capacity expressed as VO2peak 
than as 6MWD. This suggests that those who present with modest impairments in 
6MWD may have considerable impairment in peak exercise capacity, and may still 
benefit from participating in exercise training. The SpO2 of people following curative 
intent treatment for NSCLC decreased to a greater extent during the 6MWT, and 
therefore this test may assist in identifying those who desaturate during exercise. In 
contrast to people with COPD, in whom the 6MWT and CPET elicit similar peak 
VO2peak and HR response, in people following curative intent treatment for NSCLC, the 
6MWT elicited sub-maximal responses. As the 6MWT is a sub-maximal test in this 
population, it is likely that they will tolerate an initial prescription of walking-based 
training at an intensity greater than that used for COPD, which is often 80% of the 
average walking speed achieved during the 6MWT. A minimum of two 6MWTs need to 
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be performed as the 6MWD increased with test repetition. Future studies should 
investigate; (i) the optimal initial speed for the walking training prescription based on 
the average walking speed achieved during the 6MWT, (ii) the responsiveness of the 
6MWT to interventions such as exercise training, and (iii) properties of other common 
field-based walking tests such as the incremental and endurance shuttle walk test in 
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Legend of Figure 
 
Figure 1: Patterns of responses for: A) heart rate (HR) and B) peripheral capillary 
oxygen saturation (SpO2) for each test. Data are mean and standard error. All 
participants contributed to each decile (data point). ●, cardiopulmonary exercise test 
(CPET); ■, six-minute walk test. For the CPET, time 0 (zero) is the start of the ramp. 














































Abbreviations: BMI – Body-mass index; DLCO – Single breath diffusing capacity for carbon 
monoxide; FEV1 – Forced expiratory volume in one second; FVC – Forced vital capacity; NSCLC – 
Non-small cell lung cancer; SD – Standard deviation; VATS – Video-assisted thoracoscopic surgery. 
 































Abbreviations: 6MWD – Six-minute walk distance; AT – Anaerobic threshold as a 
percentage of the VO2peak; 6MWT – Six-minute walk test; 6MWW – Six-minute walk 
work; CPET – Cardiopulmonary exercise test; f R: Respiratory frequency; MVV – 
Maximum voluntary ventilation; O2 pulse – Oxygen pulse; VEmax – Maximum minute 
ventilation; VO2peak – Peak rate of oxygen consumption; Wmax – Maximum work rate. 
 












Abbreviations: 6MWT – Six-minute walk test; CPET – Cardiopulmonary exercise test; BORGd – 
Dyspnoea; BORGf – Leg fatigue; HR – Heart rate; SpO2 – Peripheral capillary oxygen saturation 
measured via pulse oximetry; ∆SpO2 – (Nadir SpO2 – initial SpO2). 
Statistically significant differences between tests: *p < 0.05; **p < 0.01 
#Maximum HR (HRmax) was calculated from the equation 220 – age. 
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mean ± SD 
Non-COPD (n=10) 
mean ± SD 
 
p value 
Age (yr) 69 ± 9   65 ± 11 0.10 
BMI (kg·m-2) 24 ± 4 28 ± 6 0.02 
Smoking (pack·yr)   42 ± 22   25 ± 18 0.001 
FEV1 (L)   1.63 ± 0.52   1.67 ± 0.48 0.18 
FEV1 (%pred)   62 ± 16   71 ± 16 0.06 
FVC (L)     2.93 ± 0.76   2.44 ± 0.63 0.02 
FVC (%pred)     83 ± 11   78 ± 10 0.11 
FEV1/FVC (%)     56 ± 11 71 ± 8 0.002 
DLCO (ml·mmHg
-1·min-1)   13 ± 4 14 ± 3 0.42 
DLCO (%pred)     48 ± 10  58 ± 10 0.02 
Abbreviations: BMI – Body-mass index; COPD – Chronic obstructive pulmonary disease; DLCO – Single 
breath diffusing capacity for carbon monoxide; FEV1 – Forced expiratory volume in one second; FVC – 
Force vital capacity. 
Results 
Cardiopulmonary exercise test 
There was no association between BORGd and BORGf reported on test completion 
(r=0.08; p=0.72).  
 
Six-minute walk test 
There was no association between BORGd and BORGf reported on test completion 
(r=0.42; p=0.07). 
 
Subgroup of people with COPD 
No differences were found in 6MWD or VO2peak between the subgroup of people with 
COPD and the subgroup of people not diagnosed with COPD (6MWD=501±92 [COPD] 
versus 506±47m [non-COPD]; VO2peak=15±3 [COPD] versus 15±3ml·kg
-1·min-1 [non-
COPD]; p>0.05 for both). 
